VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | The potential of targeting PAK6 in CML

Andrew Wu, BS, MS, British Columbia Cancer Agency, Vancouver, Canada, comments on the rationale for targeting p21-activated kinase 6 (PAK6) in chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter